Covington & Burling LLP's client base comprises major domestic and multinational pharma companies, as well as a wide array of biotech, diagnostic, medical device, cosmetic and food companies, ranging from start-up ventures to industry leaders. Key areas of strength include advising on issues related to Covid-19, incentives for innovation, reimbursement procedures, the new Medical Devices and IVD Regulations, and global pathogen-sharing rules. Peter Bogaert and Bart Van Vooren oversee the life sciences department; the latter has developed a niche practice on compliance with the Biodiversity Convention and the Nagoya Protocol.
Key clients
- AbbVie
- AstraZeneca
Work highlights
- Representing Aloe Vera of Europe in litigation before the EU General Court, including a request for suspension, against a Commission Regulation banning HAD for an infringement of the precautionary principle.